Opendata, web and dolomites

TKI resistance SIGNED

Resistance mechanisms to tyrosine kinase inhibitors in solid tumors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TKI resistance project word cloud

Explore the words cloud of the TKI resistance project. It provides you a very rough idea of what is the project "TKI resistance" about.

persistor    acquired    patient    xenografts    tki    discovery    therapies    validate    subsequent    extremely    molecular    resistance    absolute    groups    overcome    strategy    drug    successfully    probably    requisite    kinase    cellular    screens    tyrosine    combinatorial    addicted    scrutinize    involve    epigenetic    over    addiction    lines    expanded    cancer    vitro    biopsies    tolerant    populations    tolerate    guidance    interfere    few    driver    escape    cells    laboratory    sensitizers    alternative    chemotherapeutic    understand    inhibitor    additionally    patients    systematic    rational    strategies    arsenal    tkis    resistant    screen    emergence    therapeutic    inhibitors    ultimately    whereby    adaptive    modifiers    oncogene    innovative    reprogrammation    acquisition    stage    screening    translational    limited    performed    agents    elucidate    establishing    mechanisms    persistors    standardized    single    cell    models    develops    worldwide    apoptosis    treatments    designs   

Project "TKI resistance" data sheet

The following table provides information about the project.

Coordinator
INSTITUT GUSTAVE ROUSSY 

Organization address
address: Rue Camille Desmoulins 39
city: VILLEJUIF
postcode: 94805
website: http://www.igr.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.gustaveroussy.fr/fr/biomarqueurs-predictifs-nouvelles-strategies-therapeutiques-thematique
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) coordinator 1˙500˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Over the past 10 years, the chemotherapeutic arsenal has been expanded to include molecular-targeted therapies based on the principle that cancer cells become addicted to a single driver oncogene. However, use of these new therapies is limited due to development of acquired resistance. To fully understand how resistance develops, patient-derived models are an absolute pre-requisite, but establishing them remains extremely challenging. Few groups worldwide have successfully implemented a systematic standardized approach to facilitate translational cancer research discovery. My project aims to provide rational therapeutic guidance for combinatorial or adaptive designs to overcome acquired resistance to tyrosine kinase inhibitors (TKIs) in patients with oncogene-addiction. By establishing new laboratory models of resistance directly from patient biopsies (patient derived cell lines and xenografts) I will elucidate the molecular mechanisms whereby cancer cells escape targeted treatments. I will then implement innovative approaches to overcome resistance using TKI combinatorial screens, apoptosis sensitizers and by screening for epigenetic modifiers. Additionally, I will scrutinize the emergence of resistance acquisition in vitro. Current working models involve “persistor” cellular populations able to tolerate the TKI and, in a subsequent step, to become fully resistant to the drug. This drug tolerant persistor stage most probably involves epigenetic reprogrammation. An epigenetic inhibitor screen will be performed to identify agents able to interfere with the emergence of persistors and ultimately with the acquisition of TKI resistance. These results should provide an alternative strategy to validate innovative combinatorial drug strategies to avoid emergence of resistance in patients.

 Publications

year authors and title journal last update
List of publications.
2019 Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hol
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
published pages: clincanres.1104., ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-19-1104
Clinical Cancer Research 2019-10-10
2019 Francesco Facchinetti, Antoine Hollebecque, Rastilav Bahleda, Yohann Loriot, Ken A Olaussen, Christophe Massard, Luc Friboulet
Facts and new hopes on selective FGFR inhibitors in solid tumors
published pages: clincanres.2035., ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-19-2035
Clinical Cancer Research 2019-10-10
2018 Gonzalo Recondo, Francesco Facchinetti, Ken A. Olaussen, Benjamin Besse, Luc Friboulet
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
published pages: , ISSN: 1759-4774, DOI: 10.1038/s41571-018-0081-4
Nature Reviews Clinical Oncology 2019-09-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TKI RESISTANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TKI RESISTANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

EVOCELFATE (2019)

Evolution of cell fate specification modes in spiral cleavage

Read More  

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More  

SLAMseq (2019)

SLAMseq: Temporal resolution in gene expression profiling across multiple platforms

Read More